SCHEMBL10036299

SCHEMBL10036299

Nc1nc2c(c(Nc3ccc(Sc4ccncc4)cc3)n1)CCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.49
TRPV1 Q8NER1 2/20 0.41
PDE4B Q07343 2/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TOP2A P11388 1/20 0.38
PTGS1 P23219 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ACHE P22303 1/20 0.36
RAD52 P43351 1/20 0.36
FLT1 P17948 1/20 0.36
DDAH1 O94760 1/20 0.35
NOS1 P29475 1/20 0.35
HRH2 P25021 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KDR P35968 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10036317 0.84 ROCK2 (0.57) ROCK2TRPV1PDE4BKDM4EALDH1A1
SCHEMBL10036310 0.84 ROCK2 (0.56) ROCK2TRPV1KDM4EALDH1A1HPGD
SCHEMBL14340820 0.74 TUBB3 (0.47) ROCK2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL14340827 0.74 TRPV1 (0.36) TRPV1PDE4BKDM4E
SCHEMBL10036312 0.73 DHODH (0.40) TRPV1PDE4BKDM4EALDH1A1HPGD
SCHEMBL10036303 0.72 ROCK2 (0.57) ROCK2ALDH1A1MEN1KMT2ANPSR1
SCHEMBL22161454 0.72 ROCK2 (0.61) ROCK2TRPV1PDE4BALDH1A1TOP2A
SCHEMBL10036323 0.71 DHODH (0.40) TRPV1PDE4BKDM4EALDH1A1HSD17B10
SCHEMBL10036324 0.66 ROCK1 (0.68) ROCK2
SCHEMBL10036305 0.66 ROCK2 (1.00) ROCK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302587-A1 RHO-KINASE INHIBITORS NAGARAHNAM DHANAPALAN (US) 2012-11-29 US disclosed
US-20120302587-A1 RHO-KINASE INHIBITORS NAGARAHNAM DHANAPALAN (US) 2012-11-29 US disclosed
EP-1470121-B1 PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2012-07-11 EP disclosed
US-20120053179-A1 Rho-Kinase Inhibitors NAGARATHNAM DHANAPALAN (US) 2012-03-01 US disclosed
US-20120053179-A1 Rho-Kinase Inhibitors NAGARATHNAM DHANAPALAN (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053179-A1 Rho-Kinase Inhibitors CIT, ROCK1, ROCK2 ROCK2 3/4885TRPV1 4736/4885PDE4B 50/4885
US-20120302587-A1 RHO-KINASE INHIBITORS CIT, ROCK1, ROCK2 ROCK2 3/4885TRPV1 4736/4885PDE4B 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.